Thanks
@pivalde agree this is a great find.
I know it has been explained before in other threads in the past, but can anyone give quick recap on what the situation is with PBT2 and Alterity these days? Pivalde I think you've mentioned Masters has rights to PBT2 in AD with ATH getting a slice of any future revenue in that space, but is there IP protection for PBT2 in drug resistant infections and does Alterity own all or part of that IP still?
Searching PBT2 on Doherty Institute website gives a bit of a snapshot on history, this is what i've gathered;
2018: UQ, Griffith and Doherty/Unimelb research released on PBT2 potential in antimicrobial resistance
2020: More research mentioned in a Doherty release, Unimelb/Doherty's Christopher McDevitt mentions they've done animal studies and hoping to get to clinic soon
2022: In Jan McDevitt again mentions they are working toward clinic by collecting the data required for a clinical trial of PBT2 in combination with antibiotics, then in Feb Dr Stephanie Neville at Doherty under McDevitt, is awarded fellowship to progress PBT2 research. Then in Sep McDevitt gets $100k vic gov grant for research, Then December they're also granted $1.1M from NHMRC to support PBt2 development.
2023: October Mcdevitt's team wins CARB-X award getting another $2.6M to accelerate PBT2 development.
So no news since October 2023? Thanks anyone who can add to, certainly seems like a worthwhile development with a lot of research being done recently. With the Chinese publication got me wondering on the IP situation. Cheers
https://www.doherty.edu.au/templates/search-results?keywords=PBT2
(20min delay)